Important Safety Information
CORE
Get reimbursement assistance and support with CORE: Cephalon Oncology Reimbursement Expertise
Reimbursement
COPE
Get information about APL and TRISENOX with COPE: Cephalon Oncology Patient Education
Educational Materials
Register for updates or request information about reimbursement assistance



About APL: A rare blood cancer

Acute promyelocytic leukemia (APL) is a rare but serious and aggressive (fast-growing) form of leukemia which can affect people of any age. The annual incidence of newly diagnosed APL in the U.S. is approximately 1,000 to 1,500 cases, with another 2,500 to 4,000 cases occurring outside the U.S.1

APL is a subtype of the cancer known as acute myeloid leukemia (AML), and accounts for approximately 10% of AML patients.2 APL occurs when the body produces too many immature blood cells known as promyelocytes, which cannot carry out their normal functions and which block the production of normal mature blood cells.

>> Click here for more information about AML from the National Cancer Institute.
1. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001;6 Suppl 2:11-16.
2. Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol. 2005;56:261-274.














©2008 Cephalon, Inc. All rights reserved.
The information presented on this site is intended for U.S. residents only.
Cephalon Oncology